Von Eschenbach joins Greenleaf
This article was originally published in The Tan Sheet
Executive SummaryFormer FDA Commissioner Andrew von Eschenbach teams with his former chief of staff, Patrick Ronan, as a senior advisor at Greenleaf Health - a regulatory consulting firm Ronan founded in 2006 with offices in New York and Washington. Von Eschenbach says Greenleaf is a great "launching pad" to contribute to macro health care issues, such as personalized medicine, genomics and informatics. He cannot advocate directly to FDA on behalf of a third party for the next year and he has a lifetime ban on lobbying FDA on rules he influenced as commissioner. Eschenbach also says a return is in the works to the University of Texas M.D. Anderson Cancer Center in Houston, where he spent 25 years in various leadership positions before being named director of the National Cancer Institute in 2000. At M.D. Anderson he will be an adjunct professor and will serve on the advisory board of the David Koch Center for Applied Research in Genitourinary Cancers
You may also be interested in...
US investigators fan out to non-China inspection priorities and Secretary Azar talks supply management; warning letters hit record keeping, investigations and basic GMP compliance.
Mallinckrodt to pay $1.6bn and place its generics unit in bankruptcy under agreement in principle for US global settlement; six states are not on board, including New York, whose suit is still set to go to trial March 20.